Comorbidity of depression and anxiety is quite common in Parkinson's disease (PD). The ventral hippocampus (vHIP) has been widely implicated in depression and anxiety. However, the roles of CaMKⅡα-positive neurons in the vHIP in depression- and anxiety-like behaviors associated with PD in rats remain unclear. Here, we used chemogenetic techniques, such as designer receptors exclusively activated by designer drugs (DREADDs), to activate or inhibit CaMKⅡα-positive neurons in the vHIP of rats. In the present study, the unilateral 6-hydroxydopamine (6-OHDA) lesions of the medial forebrain bundle (MFB) led to depression- and anxiety-like behaviors, as well as decreased levels of dopamine (DA) but not 5-hydroxytryptamine (5-HT) in the medial prefrontal cortex (mPFC), striatum, amygdala, lateral habenula (LHb), dorsal hippocampus (dHIP) and vHIP in rats. hM3Dq-induced activation of vHIP CaMKⅡα-positive neurons produced antidepressant and anxiolytic effects, and increased DA levels in the mPFC, dHIP and vHIP only in the 6-OHDA-lesioned rats. In contrast, hM4Di-induced inhibition of vHIP CaMKⅡα-positive neurons had no effect on depression- or anxiety-like behaviors in both sham operated and the 6-OHDA-lesioned rats, but decreased DA levels in the amygdala in both groups, as well as decreased DA levels in the LHb and mPFC, and decreased 5-HT levels in the mPFC of the 6-OHDA-lesioned rats. Our findings suggest that hM3Dq-induced chemogenetic activation of vHIP CaMKⅡα-positive neurons produces antidepressant and anxiolytic effects in the 6-OHDA-lesioned rats. Meanwhile, DREADDs-induced changes in the behaviors may be related to DA and 5-HT levels in the limbic and limbic-related brain regions.
Keywords: Anxiety; DREADDs; Depression; Parkinson's disease; Ventral hippocampus.
Copyright © 2026 Elsevier B.V. All rights reserved.